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I nfliximab was shown to be effective and safe in controlled trials of psoriatic arthritis (PsA). [1] [2] [3] [4] In an open-label study, we reported a notable clinical benefit accompanied by clearing and healing of psoriatic skin lesions.
5 Thus, we conducted this study to evaluate the efficacy and safety of infliximab in patients with active PsA and recalcitrant psoriasis in whom treatment with disease-modifying antirheumatic drugs had failed. Thirty two patients who had a negative purified protein derivative skin test and normal chest radiographs were included. All had an active disease, defined as >6 tender or swollen joints count, psoriasis area and severity index (PASI) score >10, 6 and erythrocyte sedimentation rate >28 mm Hg/h or C reactive protein concentration >10 mg/l. The end points were the percentage of patients who achieved the psoriatic arthritis response criteria (PsARC) 7 and improvement in PASI. Patients were treated with infliximab (5 mg/kg weight) at weeks 0, 2 and 6 and every 8 weeks thereafter for a period of 2 years. If the clinical response was insufficient, the interval between infusions was shortened to 6 or 4 weeks. The clinical response according to the American College of Rheumatology (ACR) criteria, 8 and the disease activity for 28-joint indices score were recorded. 9 Table 1 shows the clinical and laboratory data. After the first year of treatment, PsARC was achieved by 26 of 32 (81.25%) patients, PASI 70% by 27 of 32 (84.4%) patients, and PASI 90% by 26 of 32 (81.25%) patients. After the second year, PsARC was achieved by 23 of 32 (71.9%) patients, and PASI 70% and 90% by 24 of 32 (75.0%) patients. The response to treatment was rapid, and, after 6 months of infliximab treatment, in most of the patients the skin lesions were cleared and healed. This clinical improvement was sustained for 2 years (fig 1) . A similar clinical response was seen on applying the ACR response criteria. A significant reduction in disease activity for 28-joint indices score and acute-phase reactants was noted. After the first year of treatment, 84.4% of patients continued with infliximab. This rate was 75% after the second year. Eight patients discontinued infliximab treatment: five patients due to allergic reactions, one due to lack of efficacy and two were lost to follow-up.
These results are in agreement with previous studies.
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However, our results differ somewhat from those of other investigators, who assessed primarily the articular component of the disease and, to a lesser extent, the cutaneous manifestations. In addition, no infliximab survival rates have been
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